Methods and compositions for treating cancer

Abstract

Methods and compositions for treating cancer are described herein. More particularly, the methods for treating cancer comprise administering a 17α-hydroxylase/C 17,20 -lyase inhibitor, such as abiraterone acetate (i.e., 3β-acetoxy-17-(3-pyridyl)androsta-5,16-diene), in combination with at least one additional therapeutic agent such as an anti-cancer agent or a steroid. Furthermore, disclosed are compositions comprising a 17α-hydroxylase/C 17,20 -lyase inhibitor, and at least one additional therapeutic agent, such as an anti-cancer agent or a steroid.

1 - 56 . (canceled) 
     
     
         57 . A method for the treatment of a prostate cancer in a human comprising administering to said human a composition comprising a therapeutically effective amount of abiraterone acetate or a pharmaceutically acceptable salt thereof and a therapeutically effective amount of prednisone. 
     
     
         58 . The method of  claim 57 , wherein each of the composition is for oral administration. 
     
     
         59 . The method of  claim 58 , wherein the composition comprises separate compositions of each of abiraterone acetate and prednisone or abiraterone acetate and prednisone combined into a single composition. 
     
     
         60 . The method of  claim 58 , wherein the composition comprises a separate composition for each of abiraterone acetate and prednisone. 
     
     
         61 . The method of  claim 60 , wherein the therapeutically effective amount of the abiraterone acetate is from about 50 mg/day to about 2000 mg/day. 
     
     
         62 . The method of  claim 61 , wherein the therapeutically effective amount of the abiraterone acetate or pharmaceutically acceptable salt thereof is from about 500 mg/day to about 1500 mg/day. 
     
     
         63 . The method of  claim 62 , wherein the therapeutically effective amount of the abiraterone acetate or pharmaceutically acceptable salt thereof is about 1000 mg/day. 
     
     
         64 . The method of  claim 63 , wherein the therapeutically effective amount of the abiraterone acetate is administered in at least one dosage form comprising about 250 mg of abiraterone acetate. 
     
     
         65 . The method of  claim 60 , wherein the therapeutically effective amount of the prednisone is from about 0.01 mg/day to about 500 mg/day. 
     
     
         66 . The method of  claim 65 , wherein the therapeutically effective amount of the prednisone is from about 10 mg/day to about 250 mg/day. 
     
     
         67 . The method of  claim 66 , wherein the therapeutically effective amount of the prednisone is about 10 mg/day. 
     
     
         68 . The method of  claim 66 , wherein the therapeutically effective amount of the prednisone is administered in at least one dosage form comprising about 5 mg of prednisone. 
     
     
         69 . The method of  claim 61 , wherein the therapeutically effective amount of the prednisone is from about 0.01 mg/day to about 500 mg/day. 
     
     
         70 . The method of  claim 69 , wherein the therapeutically effective amount of the prednisone is from about 10 mg/day to about 250 mg/day. 
     
     
         71 . The method of  claim 70 , wherein the therapeutically effective amount of the prednisone is about 10 mg/day. 
     
     
         72 . The method of  claim 70 , wherein the therapeutically effective amount of the prednisone is administered in at least one dosage form comprising about 5 mg of prednisone. 
     
     
         73 . The method of  claim 62 , wherein the therapeutically effective amount of the prednisone is from about 0.01 mg/day to about 500 mg/day. 
     
     
         74 . The method of  claim 73 , wherein the therapeutically effective amount of the prednisone is from about 10 mg/day to about 250 mg/day. 
     
     
         75 . The method of  claim 74 , wherein the therapeutically effective amount of the prednisone is about 10 mg/day. 
     
     
         76 . The method of  claim 74 , wherein the therapeutically effective amount of the prednisone is administered in at least one dosage form comprising about 5 mg of prednisone. 
     
     
         77 . The method of  claim 63 , wherein the therapeutically effective amount of the prednisone is from about 0.01 mg/day to about 500 mg/day. 
     
     
         78 . The method of  claim 77 , wherein the therapeutically effective amount of the prednisone is from about 10 mg/day to about 250 mg/day. 
     
     
         79 . The method of  claim 78 , wherein the therapeutically effective amount of the prednisone is about 10 mg/day. 
     
     
         80 . The method of  claim 64 , wherein the therapeutically effective amount of the prednisone is administered in at least one dosage form comprising about 5 mg of prednisone. 
     
     
         81 . The method of  claim 65 , wherein the therapeutically effective amount of the prednisone is from about 0.01 mg/day to about 500 mg/day. 
     
     
         82 . The method of  claim 66 , wherein the therapeutically effective amount of the prednisone is from about 10 mg/day to about 250 mg/day. 
     
     
         83 . The method of  claim 82 , wherein the therapeutically effective amount of the prednisone is about 10 mg/day. 
     
     
         84 . The method of  claim 82 , wherein the therapeutically effective amount of the prednisone is administered in at least one dosage form comprising about 5 mg of prednisone. 
     
     
         85 . The method of  claim 60 , wherein the composition comprises about 500 mg/day to about 1500 mg/day of abiraterone acetate and about 0.01 mg/day to about 500 mg/day of prednisone. 
     
     
         86 . The method of  claim 85 , wherein the composition comprises about 1000 mg/day of abiraterone acetate and about 10 mg/day of prednisone.